Eye health has been in and out of sight and mind for some time now, urging organisations to demand greater investment and attention towards Aussies’ unmet needs. In 2018, 93% of Aussies aged over 65 reported vision disorders, and the pandemic did little to help by not being a sight for sore eyes. If that
Read More
With improvements in allied healthcare, the 134 million people worldwide diagnosed with glaucoma is likely to increase with better diagnostics, but also ensure earlier detection which can be treated sooner as evidenced by medtech company Nova Eye Medical (ASX: EYE) and rising sales of their advanced ophthalmic treatment technologies and devices. As the developers and
Read More
The 60 million individuals around the world who suffer from glaucoma could one day have a cure for the debilitating eye disease from NeuroScientific Biopharmaceuticals (ASX: NSB), with the company buoyed by initial results from their preclinical trials. The drug development company’s lead product, EmtinB – a therapeutic peptide which has had positive results for
Read More